Ionis Pharmaceuticals Inc (IONS)

60.00 -0.13  -0.22% NASDAQ Jan 21, 16:58 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
02/27/2020 11:30 EST Misc Ionis Pharmaceuticals Inc Fourth Quarter Earnings Conference Call in 2019
02/27/2020 Earnings Ionis Pharmaceuticals Inc Fourth Quarter Earnings in 2019 Release
11/06/2019 11:30 EST Misc Ionis Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2019
11/06/2019 Earnings Ionis Pharmaceuticals Inc Third Quarter Earnings in 2019 Release
08/07/2019 11:30 EDT Misc Ionis Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2019
08/07/2019 Earnings Ionis Pharmaceuticals Inc Second Quarter Earnings in 2019 Release
06/06/2019 14:00 PDT Misc Ionis Pharmaceuticals Inc Annual General Meeting in 2018
05/09/2019 11:30 EDT Misc Ionis Pharmaceuticals Inc First Quarter Earnings Conference Call in 2019
05/09/2019 Earnings Ionis Pharmaceuticals Inc First Quarter Earnings in 2019 Release
03/01/2019 Misc Ionis Pharmaceuticals Inc Annual Report in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.ionispharma.com
  • Investor Relations URL: http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-irhome
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Feb. 27, 2020
  • Last Earnings Release: Nov. 06, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline treats a wide variety of diseases, with an emphasis on cardiovascular, metabolic, severe, and rare diseases. Ionis sold rights to its first product, Kynamro, to Kastle Therapeutics after lackluster commercial success, but with partner Biogen brought its second drug, Spinraza for spinal muscular atrophy, to market. ATTR amyloidosis drug Tegsedi (inotersen) was approved in 2018 and cardiology drug Waylivra was approved in Europe in 2019.

Top Fund Holders

Symbol Name Weighting
FBT First Trust NYSE Arca Biotech ETF 3.32%
ARKG ARK Genomic Revolution ETF 2.93%
BTEC Principal Healthcare Innovators ETF 2.09%
LMPFX ClearBridge Aggressive Growth FI 1.90%
BBH VanEck Vectors Biotech ETF 1.71%
FBIOX Fidelity® Select Biotechnology 1.66%
XBI SPDR® S&P Biotech ETF 1.65%
WSTBX Ivy Science And Technology B 1.51%
FCGSX Fidelity® Series Growth Company 1.38%
HFMRX Hartford MidCap R3 1.30%
FGCKX Fidelity® Growth Company K 1.21%
IBB iShares Nasdaq Biotechnology ETF 1.02%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.